. Author manuscript; available in PMC: 2012 Apr 27.

Published in final edited form as: Support Care Cancer. 2010 May 25;19(6):833–841. doi: 10.1007/s00520-010-0911-0

Table 2. Exposure to neurotoxic agents at baseline (participants may have been exposed to more than one agent).

Agent	Previous treatment only percent of patients		Concurrent treatment percent of patients

	BAK (N=101)	Placebo (N=102)	BAK (N=101)	Placebo (N=102)
Vinca alkaloids	3	5	3	5
Oxaliplatin	31	33	12	13
Cisplatin	13	21	4	2
Taxanes	40	41	12	5
Thalidomide	3	2	0	0
Other	7	3	2	5